Liraglutide and Renal Outcomes in Type 2 Diabetes.

PubWeight™: 4.42‹?› | Rank: Top 1%

🔗 View Article (PMID 28854085)

Published in N Engl J Med on August 31, 2017

Authors

Johannes F E Mann1, David D Ørsted1, Kirstine Brown-Frandsen1, Steven P Marso1, Neil R Poulter1, Søren Rasmussen1, Karen Tornøe1, Bernard Zinman1, John B Buse1, LEADER Steering Committee and Investigators

Author Affiliations

1: From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen, Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.Ø., K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and University of North Carolina School of Medicine, Chapel Hill (J.B.B.).

Associated clinical trials:

Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems (DIASMOKE) | NCT04231838